Endymed
Endymed Ltd provides energy based medical aesthetic treatment systems for the professional and consumer markets in North America, Europe, the Middle East, Africa, Asia, Oceania, Latin America, and internationally. The company offers ENDYMED PRO, an all-in-one treatment platform; ENDYMED PURE 2.0, a compact and flexible treatment platform; Pure Laser, a laser hair removal system; Intensif, a RF mi… Read more
Endymed (ENDY) - Net Assets
Latest net assets as of September 2024: ILA13.24 Million ILA
Based on the latest financial reports, Endymed (ENDY) has net assets worth ILA13.24 Million ILA as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ILA18.21 Million) and total liabilities (ILA4.96 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ILA13.24 Million |
| % of Total Assets | 72.75% |
| Annual Growth Rate | -0.29% |
| 5-Year Change | 87.03% |
| 10-Year Change | -48.52% |
| Growth Volatility | 127.34 |
Endymed - Net Assets Trend (2008–2023)
This chart illustrates how Endymed's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Endymed (2008–2023)
The table below shows the annual net assets of Endymed from 2008 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | ILA15.27 Million | +3.87% |
| 2022-12-31 | ILA14.70 Million | +6.87% |
| 2021-12-31 | ILA13.76 Million | +62.42% |
| 2020-12-31 | ILA8.47 Million | +3.73% |
| 2019-12-31 | ILA8.17 Million | +27.61% |
| 2018-12-31 | ILA6.40 Million | +403.07% |
| 2017-12-31 | ILA1.27 Million | -68.44% |
| 2016-12-31 | ILA4.03 Million | -35.09% |
| 2015-12-31 | ILA6.21 Million | -79.07% |
| 2014-12-31 | ILA29.66 Million | +171.04% |
| 2013-12-31 | ILA10.95 Million | -6.56% |
| 2012-12-31 | ILA11.71 Million | +16.97% |
| 2011-12-31 | ILA10.01 Million | -39.04% |
| 2010-12-31 | ILA16.43 Million | +233.66% |
| 2009-12-31 | ILA4.92 Million | -69.14% |
| 2008-12-31 | ILA15.95 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Endymed's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3725600000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ILA20.61 Million | 134.91% |
| Total Equity | ILA15.27 Million | 100.00% |
Endymed Competitors by Market Cap
The table below lists competitors of Endymed ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
STRAIT MINERALS
F:S5G
|
$118.29K |
|
BlackRock Limited Duration Income Trust
NYSE:BLW
|
$118.42K |
|
Brookfield Real Assets Income
NYSE:RA
|
$118.43K |
|
Fidia S.p.A.
F:FIC0
|
$118.45K |
|
Targeted Microwave Solutions Inc
PINK:TGTMF
|
$118.02K |
|
IA Invest Global Health Invest
CO:IAIGHI
|
$117.98K |
|
PS Business Parks Inc.
PINK:PSBYP
|
$117.94K |
|
Infrastructure Dividend Split Corp.
TO:IS
|
$117.93K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Endymed's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 14,704,000 to 15,273,000, a change of 569,000 (3.9%).
- Net income of 553,000 contributed positively to equity growth.
- New share issuances of 4,000 increased equity.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ILA553.00K | +3.62% |
| Share Issuances | ILA4.00K | +0.03% |
| Other Changes | ILA12.00K | +0.08% |
| Total Change | ILA- | 3.87% |
Book Value vs Market Value Analysis
This analysis compares Endymed's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 288.43x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 2373.05x to 288.43x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ILA0.13 | ILA320.10 | x |
| 2018-12-31 | ILA0.47 | ILA320.10 | x |
| 2019-12-31 | ILA0.59 | ILA320.10 | x |
| 2020-12-31 | ILA0.62 | ILA320.10 | x |
| 2021-12-31 | ILA1.00 | ILA320.10 | x |
| 2022-12-31 | ILA1.07 | ILA320.10 | x |
| 2023-12-31 | ILA1.11 | ILA320.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Endymed utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.62%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.43%
- • Asset Turnover: 1.11x
- • Equity Multiplier: 1.34x
- Recent ROE (3.62%) is above the historical average (-47.10%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | -110.99% | -3988.06% | 0.02x | 1.40x | ILA-19.30 Million |
| 2009 | -249.85% | -155.87% | 0.62x | 2.57x | ILA-12.79 Million |
| 2010 | -22.40% | -52.84% | 0.32x | 1.31x | ILA-5.32 Million |
| 2011 | -67.96% | -219.83% | 0.24x | 1.27x | ILA-7.81 Million |
| 2013 | -3.30% | -1.71% | 1.00x | 1.93x | ILA-1.46 Million |
| 2014 | 0.68% | 0.53% | 0.74x | 1.75x | ILA-2.77 Million |
| 2015 | -61.67% | -29.57% | 1.11x | 1.88x | ILA-4.45 Million |
| 2016 | -82.11% | -23.22% | 1.37x | 2.58x | ILA-3.71 Million |
| 2017 | -212.34% | -15.40% | 1.99x | 6.92x | ILA-2.83 Million |
| 2018 | 31.58% | 10.95% | 1.57x | 1.84x | ILA1.38 Million |
| 2019 | 21.38% | 10.62% | 1.17x | 1.73x | ILA929.40K |
| 2020 | 3.64% | 2.15% | 1.06x | 1.60x | ILA-539.10K |
| 2021 | 37.52% | 23.70% | 1.11x | 1.42x | ILA3.79 Million |
| 2022 | 5.78% | 3.98% | 1.08x | 1.34x | ILA-620.40K |
| 2023 | 3.62% | 2.43% | 1.11x | 1.34x | ILA-974.30K |
Industry Comparison
This section compares Endymed's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $49,120,889
- Average return on equity (ROE) among peers: -6.67%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Endymed (ENDY) | ILA13.24 Million | -110.99% | 0.37x | $118.10K |
| Allmed Solutions Ltd (ALMD) | $45.13 Million | -46.38% | 0.26x | $96.61K |
| Erika Carmel Ltd (BCUR) | $8.97 Million | 138.94% | 4.32x | $46.92K |
| Bio-View Ltd (BIOV) | $23.45 Million | -5.34% | 0.48x | $54.59K |
| Erech Finance Cahalacha Ltd (EFNC) | $-63.00K | 0.00% | 0.00x | $19.28K |
| Epitomee Medical Ltd (EPIT) | $34.80 Million | -16.33% | 0.16x | $567.43K |
| Human Xtensions Ltd (HUMX) | $61.78 Million | -72.18% | 0.17x | $21.16K |
| Ilex Medical (ILX) | $109.44 Million | 17.00% | 0.55x | $2.01 Million |
| Pulsenmore Ltd (PULS) | $132.23 Million | -44.29% | 0.36x | $321.83K |
| Sofwave Medical Ltd (SOFW) | $26.34 Million | -31.42% | 0.65x | $3.18 Million |